1. Home
  2. TECX vs ENTA Comparison

TECX vs ENTA Comparison

Compare TECX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$29.47

Market Cap

393.0M

Sector

N/A

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.57

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
ENTA
Founded
2019
1995
Country
United States
United States
Employees
51
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
393.0M
374.6M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
TECX
ENTA
Price
$29.47
$12.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$80.40
$20.40
AVG Volume (30 Days)
323.2K
170.9K
Earning Date
05-07-2026
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.93
EPS
N/A
N/A
Revenue
N/A
$102,814,000.00
Revenue This Year
N/A
$7.76
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.48
52 Week Low
$13.70
$4.09
52 Week High
$35.99
$17.15

Technical Indicators

Market Signals
Indicator
TECX
ENTA
Relative Strength Index (RSI) 54.30 40.63
Support Level $16.83 $12.09
Resistance Level $35.99 $15.52
Average True Range (ATR) 2.85 0.81
MACD -0.27 -0.17
Stochastic Oscillator 55.28 2.50

Price Performance

Historical Comparison
TECX
ENTA

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: